--- title: "Enveric Biosciences falls short of Nasdaq $2,500,000 stockholders' equity rule" url: "https://aibio.space/news/enveric-biosciences-falls-short-nasdaq-2-500-000-stockholders-equity/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-08-29" section: "Listings" tickers: "NASDAQ:ENVB" source: "https://www.sec.gov/Archives/edgar/data/890821/000164117225026040/form8-k.htm" summary: "Nasdaq's deficiency letter came after the company reported stockholders' equity of $2,184,769 at June 30, 2025, below the $2,500,000 minimum for the Nasdaq" --- By the aibio.space news desk. Sources - [Enveric Biosciences, Inc. 8-K (2025-08-29)](https://www.sec.gov/Archives/edgar/data/890821/000164117225026040/form8-k.htm) [ENVB](https://aibio.space/companies/enveric-biosciences/) 2025-08-29 # Enveric Biosciences falls short of Nasdaq $2,500,000 stockholders' equity rule Tickers [ENVB](https://aibio.space/companies/enveric-biosciences/) Nasdaq's deficiency letter came after the company reported stockholders' equity of $2,184,769 at June 30, 2025, below the $2,500,000 minimum for the Nasdaq Capital Market. Enveric has until October 10, 2025 to submit a plan to regain compliance. ## Key facts - **Company**: Enveric Biosciences, Inc. (NASDAQ: ENVB) - **News type**: Listings - **Primary source**: [Enveric Biosciences, Inc. 8-K (2025-08-29)](https://www.sec.gov/Archives/edgar/data/890821/000164117225026040/form8-k.htm) *A supreme court building with lit columns. CC0, via rawpixel. The picture shows the field, not the companies named.* Enveric Biosciences, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market on August 26, 2025. The letter says the company is not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. The company disclosed the letter in a [Form 8-K](https://www.sec.gov/Archives/edgar/data/890821/000164117225026040/form8-k.htm) dated August 26, 2025 and filed August 29, 2025. ## The rule and the company's figures Nasdaq Listing Rule 5550(b)(1) requires companies on the Nasdaq Capital Market to keep stockholders' equity of at least $2,500,000. The company's quarterly report on Form 10-Q for the period ended June 30, 2025 reported stockholders' equity of $2,184,769. The 8-K does not give a later equity figure. The 8-K also says the company does not meet the alternative standards Nasdaq accepts in place of the equity test. Those are a market value of listed securities of $35 million, or net income from continued operations of $500,000 in the most recently completed fiscal year or in two of the last three fiscal years. The filing does not state the company's market value of listed securities on the date of the letter. The letter has no immediate effect on the listing, subject to Enveric meeting the other continued listing requirements. Under Nasdaq rules the company has 45 calendar days, or until October 10, 2025, to submit a plan to regain compliance. If Nasdaq staff accept the plan, they may grant an extension of 180 calendar days from the date of the staff notification. If they reject it, the company may appeal to a Nasdaq Hearings Panel. ## What the company says it will do Enveric says it intends to submit the compliance plan on or before October 10, 2025, to monitor its stockholders' equity and, if appropriate, to consider further options to regain compliance. The 8-K does not describe the plan, name a source of new equity or say how much capital the company would need to raise to reach $2,500,000. ## The business behind the equity figure Enveric's business is built around the Psybrary, a library of molecules it developed after its 2021 amalgamation with MagicMed Industries Inc. The annual report filed March 28, 2025 says the Psybrary holds 20 patent families with claims covering a million potential molecular structures, and that more than one thousand of those structures have been synthesized in sufficient quantities to identify. Hundreds have been screened for receptor binding and other activities. The lead drug candidate is EB-003, which the annual report describes as a first-in-class approach to difficult-to-address mental health disorders. The company also unveiled an EVM401 Series on February 25, 2025, which it says is meant to broaden its pipeline of non-hallucinogenic molecules. Some of the work has also been handed to others. The annual report says Enveric out-licensed its EVM201 Series program, including the lead candidate EB-002, to MycoMedica Life Sciences in exchange for development and milestone payments. It also says the company is soliciting requests for proposals to license or sell its PsyAI trademark portfolio, with the period open until August 31, 2025 and a decision expected within three months after that. The report adds that the company has entered into several non-binding term sheets with strategic partners to out-license certain Psybrary molecules. The annual report calls the term sheets non-binding and gives no timetable for turning them into agreements that could add revenue or cash. The equity shortfall therefore sits beside licensing deals not yet signed. The annual report also describes EB-003 only in terms of what it is intended to do, with no clinical results. ## Timing The letter gives Enveric until October 10, 2025 for its plan. If Nasdaq accepts the plan, the company would have up to 180 calendar days from the staff notification to regain compliance. Enveric's stock trades on the Nasdaq Capital Market under the symbol ENVB, and the 8-K lists the company's principal executive offices in Naples, Florida. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story ENVB Enveric Biosciences, Inc. NASDAQ ยท United States Open the starter desk ## More in Listings Listings ### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/) Oct 29, 2026 Listings ### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/) Oct 29, 2026 Listings ### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/) Oct 28, 2026 --- Source page: https://aibio.space/news/enveric-biosciences-falls-short-nasdaq-2-500-000-stockholders-equity/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Enveric Biosciences falls short of Nasdaq $2,500,000 stockholders' equity rule", 2025-08-29, https://aibio.space/news/enveric-biosciences-falls-short-nasdaq-2-500-000-stockholders-equity/